oliver zhong

Oliver Zhong

Special Senior Adviser and New Economy Team Leader (Greater China), Hong Kong SAR

“Innovation is the fountain of economic growth and social change. For nearly 15 years, I have focused on helping innovative companies raise capital from public markets, guiding them through transformative milestones such as IPOs and bond issues. I take pride in being a trusted adviser for my clients as they navigate these critical phases and seeing them emerge as better companies.”

Overview

Education and qualifications

Published works

Overview

Oliver Zhong is a Special Senior Adviser and New Economy Team Leader (Greater China). 

Oliver is well reputed and has extensive experience in advising multinational and Chinese corporates and financial institutions on corporate finance and capital markets transactions, including Hong Kong and U.S.-registered initial public offerings and debt offerings under Rule 144A and Regulation S, with a focus on issuers in the healthcare, consumer, technology and real estate sectors. Oliver is recognised as a Notable Practitioner in Hong Kong equity capital markets by IFLR 2023.

Work highlights

Highlights of Oliver’s work representations include:

  • Hong Kong IPOs in the healthcare sector, including Qyuns Therapeutics (the first HK-listed biotech exclusively focused on immunology), MicroPort NeuroTech and MicroPort MedBot (both carve-out listings from HK-listed MicroPort Scientific Corporation), Ocumension Therapeutics (the first HK-listed biotech specialized in ophthalmology), Zhaoke Ophthalmology (carve-out listing from HK-listed Lee’s Pharm Group), Shanghai Henlius Biotech (a dual-level spin-off from HK-listed Fosun International and HK- and A shares-listed Fosun Pharma), Alphamab Oncology and Suzhou Basecare Medical, as well as convertible bond offerings by Viva Biotech Holdings.*
  • Hong Kong IPOs of Beijing UBOX Online Technology, YH Entertainment Group, China Youran Dairy Group, ManpowerGroup Greater China (carve-out listing from NYSE-listed ManpowerGroup), BabyTree Group, Changjiu Holdings, LC Logistics, Sunshine 100 China Holdings and PanAsialum Holdings, as well as the listing of SouFun Holdings on the New York Stock Exchange.*
  • Over 130 Rule 144A and Regulation S “high yield” debt offerings, including those conducted by CAR Inc., Guangzhou R&F, Shimao Property, Hilong Holding, CIFI Holdings, Modern Land China, Longfor Properties, SOHO China, China Oil & Gas Group and China Logistics Property Holdings.*
  • Investment-grade, “cov lite” debt offerings, including Haidilao International Holding’s landmark debut offering of US$600 million 2.150% notes due 2026 (the first global bond offering by a Chinese catering company), Fosun International’s offering of €400 million 4.35% senior notes (the first successful offering of its kind from the PRC private sector), and the offerings by Tingyi Holding (Master Kang) and Golden Eagle Retail Group.*
  • Exchange and tender offers and consent solicitations, including Fosun International, Guangzhou R&F, Hilong Holding, Modern Land China, China Fortune Land Development and Kaisa Group.*
  • Offshore restructuring, including Hilong Holding’s restructuring of its offshore U.S. dollar–denominated notes through a scheme of arrangement in the Cayman Islands (the first completed offshore restructuring in the PRC oil and gas sector).*
 
 
 
*Denotes experience from previous firm

Education and qualifications

  • University of Michigan Law School, J.D., 2008 
  • University of Texas at Austin, M.P.A., 2004 
  • Shanghai International Studies University, LL.B., 2002

Oliver speaks fluent English and Mandarin.

 

 

Published works

Oliver authored an article entitled “Dawn of a New Constitutional Era or Opportunity Wasted? An Intellectual Reappraisal of China’s Anti-Monopoly Law” in the Columbia Journal of Asian Law, 2010.